We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 06, 2020

FOLFOXIRI + Bevacizumab vs Doublets +Bevacizumab as Initial Therapy in Unresectable Metastatic Colorectal Cancer

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer
J. Clin. Oncol 2020 Aug 20;[EPub Ahead of Print], C Cremolini, C Antoniotti, A Stein, J Bendell, T Gruenberger, D Rossini, G Masi, E Ongaro, H Hurwitz, A Falcone, HJ Schmoll, M Di Maio

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading